Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VLA1553 full dose · 1 trial · 1 indication
Frequency and severity of solicited injection site and solicited systemic reactions within 14 days post-vaccination.
| Arm | Type | Description |
|---|---|---|
| VLA1553 full dose | EXPERIMENTAL | - |
| VLA1553 half dose | EXPERIMENTAL | - |
| Control | ACTIVE_COMPARATOR | Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization |
| Name | Type | Description |
|---|---|---|
| VLA1553 full dose | BIOLOGICAL | Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate |
| VLA1553 half dose | BIOLOGICAL | Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate |
| Control | BIOLOGICAL | Nimenrix |
Inclusion Criteria: 1. Male or female healthy children aged 7 to 11 years for Stratum A, 3 to 6 years for Stratum B and 1 to 2 years for Stratum C at the time of vaccination; 2. Written informed consent by the participant's parent(s)/Legally Acceptable Representative(s) ((LAR(s)), according to loca...
VLA1553 full dose is an investigational drug being studied for the prevention of Chikungunya Virus Infection. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in healthy children aged 1 to 11 years.
VLA1553 full dose is a monoclonal antibody. The specific molecular target of VLA1553 full dose has not been disclosed in the available information. It is being studied for its potential to prevent Chikungunya Virus Infection.
VLA1553 full dose is being developed by Valneva SE, a biopharmaceutical company. Valneva SE is publicly traded under the ticker symbol VALN. The company is conducting clinical trials to evaluate the safety and efficacy of VLA1553 full dose.
VLA1553 full dose is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the prevention of Chikungunya Virus Infection in pediatric populations.
VLA1553 full dose has one completed Phase 2 clinical trial registered as NCT06106581. This trial, titled 'A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years', enrolled 304 participants in the Dominican Republic and Honduras. The trial was randomized, double-blind, and active-controlled.
VLA1553 full dose is a specific formulation or dosing regimen of the drug VLA1553. The full dose designation distinguishes it from other potential doses of the same drug. Both refer to the same investigational product being developed by Valneva SE for Chikungunya Virus Infection.